secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001549595-24-000086
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025
--------------------------------------------------------------------------------

- Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.
- Heavily pretreated population: median 4 prior therapies (96.8% BTKi, 90.3% BCL2i, 25.8% non-covalent BTKi).
- 43.3% had BTK mutations, 20% PLCG2 mutations, 46.7% TP53 mutations; CNS involvement in 2 patients responded.
- NX-5948 well tolerated; common adverse events: purpura/contusion, thrombocytopenia, neutropenia.
- Company plans to initiate pivotal, registration-directed trial(s) for NX-5948 in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/0001549595-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000086/nrix-20240616.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer